August 26, 2025- Genentech broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast. The 65,000 m² facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.
Genentech’s initial investment in North Carolina is estimated at more than $700 million and is part of Roche’s $50 billion commitment to invest in US manufacturing infrastructure and R&D. The facility will create more than 1,900 jobs.
The new facility is expected to be completed and operational by 2029, incorporating modern biomanufacturing technologies, as well as advanced automation and digital capabilities. The 400,000 m² lot includes space for future expansion.